600535 Stock Overview
Engages in the pharmaceutical business in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Tasly Pharmaceutical Group Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.76 |
| 52 Week High | CN¥17.77 |
| 52 Week Low | CN¥12.24 |
| Beta | 0.46 |
| 1 Month Change | 0.14% |
| 3 Month Change | -1.34% |
| 1 Year Change | 2.93% |
| 3 Year Change | 8.69% |
| 5 Year Change | -12.46% |
| Change since IPO | 339.47% |
Recent News & Updates
Recent updates
Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Nov 17
Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?
Jul 22Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Jun 13The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet
May 13Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively
Apr 26Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?
Mar 15Shareholder Returns
| 600535 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.2% | -0.7% | -0.8% |
| 1Y | 2.9% | 3.4% | 15.4% |
Return vs Industry: 600535 matched the CN Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: 600535 underperformed the CN Market which returned 15.4% over the past year.
Price Volatility
| 600535 volatility | |
|---|---|
| 600535 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 600535 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600535's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 9,223 | Jing Su | www.taslypharma.com |
Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. It provides cardiovascular, anti-tumor, cold and fever, liver disease treatment, and other disease solutions. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is based in Tianjin, China.
Tasly Pharmaceutical Group Co., Ltd Fundamentals Summary
| 600535 fundamental statistics | |
|---|---|
| Market cap | CN¥22.05b |
| Earnings (TTM) | CN¥881.05m |
| Revenue (TTM) | CN¥8.57b |
25.0x
P/E Ratio2.6x
P/S RatioIs 600535 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600535 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.57b |
| Cost of Revenue | CN¥2.85b |
| Gross Profit | CN¥5.71b |
| Other Expenses | CN¥4.83b |
| Earnings | CN¥881.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 04, 2025
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 66.70% |
| Net Profit Margin | 10.29% |
| Debt/Equity Ratio | 16.2% |
How did 600535 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield112%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 00:32 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tasly Pharmaceutical Group Co., Ltd is covered by 32 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Jun Liu | Changjiang Securities Co. LTD. |
| Fusheng Cheung | China Galaxy International Securities (Hong Kong) |